Best of Hematology and Breast Cancer 2026 - Nashville

Best of Hematology and Breast Cancer 2026 is organized by Binaytara Foundation (BTF) and will be held from Feb 06 - 07, 2026 at Sheraton Grand Nashville Downtown, Nashville, Tennessee, United States of America.

Description:
The Best of Hematology and Breast Cancer 2026, Nashville is a CME/CE-accredited, in-person cancer conference. This annual hematology and oncology conference brings together physicians, nurses, pharmacists, and other healthcare professionals to review the most recent advancements in the management of hematologic malignancies and breast cancer.

This two-day oncology symposium delivers high-impact updates that can be directly applied to clinical practice. Through a dynamic mix of didactic lectures, case-based discussions, tumor board-style reviews, and interactive debates, participants will explore evolving standards of care, new treatment strategies, and real-world applications for improving outcomes. By emphasizing a multidisciplinary approach, the program is designed not only for oncologists and hematologists but also for physician assistants, nurse practitioners, pharmacists, nurses, and all members of the cancer care team. In addition, networking breaks, exhibits, and receptions offer opportunities to collaborate with peers, learn from thought leaders, and connect with industry partners.

Learning Objectives:
By the end of this conference, participants will be able to:

• Summarize the most clinically relevant updates from ASH25 and SABCS25, with emphasis on their impact in hematology and breast cancer care.
• Evaluate new and emerging therapeutic strategies, including their indications, contraindications, and potential to improve patient outcomes.
• Critically analyze recent clinical trial data and expert guideline updates to determine how they inform current standards of care.
• Integrate advances in diagnostics, prognostics, and treatment approaches into personalized, evidence-based management of patients with hematologic disorders and breast cancer.